Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients
Authors:
Open Access
- 16 December 2016
- Vol. 123 (8) , 1354-1362
Abstract
BACKGROUND: Treatment methods for intrahepatic cholangiocarcinoma (ICC) have improved, but their impact on outcome remains unclear. We evaluated the outcomes of patients definitively treated with resection, radiation, and chemotherapy for ICC, stratified by era.METHODS: Clinico‐pathologic characteristics, cause of death, disease‐specific survival (DSS), and intrahepatic progression‐free survival (IPFS) were compared among patients who underwent resection, radiation, or chemotherapy as definitive treatment strategies for ICC (without distant organ metastasis) between 1997 and 2015. Variables were also analyzed by era (1997‐2006 [early] or 2007‐2015 [late]) within each group.RESULTS: Among 362 patients in our cohort, 122 underwent resection (early, 38; late, 84), 85 underwent radiation (early, 17; late, 68), and 148 underwent systemic chemotherapy alone (early, 51; late, 97) as definitive treatment strategies, and 7 patients received best supportive care. In the resection group, the 3‐year DSS rate was 58% for the early era and 67% for the late era (P = .036), and the 1‐year IPFS was 50% for the early era and 75% for the late era (P = .048). In the radiation group, the 3‐year DSS was 12% for the early era and 37% for the late era (P = .048), and the 1‐year IPFS was 48% for the early era and 64% for the late era (P = .030). In the chemotherapy group, DSS and IPFS did not differ by era. Patients treated with chemotherapy developed liver failure at the time of death significantly more frequently than patients treated with resection (P < .001) or radiation (P < .001). Multivariable analysis identified local therapy (resection or radiation) as a sole predictor of death without liver failure.CONCLUSION: Survival outcomes have improved for local therapy‐based definitive treatment strategies for ICC, which may be attributable to maintaining control of intrahepatic disease, thereby reducing the occurrence of death due to liver failure. Cancer 2017;123:1354–1362. © 2016 American Cancer Society.Keywords
Funding Information
- National Institutes of Health
This publication has 32 references indexed in Scilit:
- Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after SurgeryWorld Journal of Surgery, 2016
- Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2016
- Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic CholangiocarcinomaJAMA Surgery, 2015
- Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 CasesJournal of Gastrointestinal Surgery, 2015
- Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control studyHepatology, 2013
- Surgical Approach for Long-term Survival of Patients With Intrahepatic CholangiocarcinomaArchives of Surgery, 2012
- Causes of death in patients with hepatitis B: A natural history cohort study in the United StatesHepatology, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with SurvivalAnnals of Surgical Oncology, 2009
- Limitations of conventionally derived chronic liver disease mortality ratesHepatology, 2007